A patient presents with reduced motivation, flat affect, minimal spontaneous speech, and social withdrawal, but reports no hallucinations and holds no unusual beliefs. Which symptom category does this presentation primarily represent?
APositive symptoms — the patient has experiences added to ordinary consciousness
BNegative symptoms — the presentation reflects a subtraction of normal psychological functions
CCognitive symptoms — the primary deficit is in memory and executive function
DDisorganized symptoms — the patient's behavior is erratic and unpredictable
This is classic negative symptoms: avolition (reduced motivation), flat affect (diminished emotional expression), and alogia (reduced speech) are all 'negative' in the sense of subtracting normal functions. No hallucinations, delusions, or thought disorganization are present, so positive symptoms are absent. The 'positive/negative' distinction reflects addition versus subtraction of experience — not good versus bad outcomes. This distinction matters clinically because antipsychotic medications are effective against positive symptoms but show limited efficacy against negative ones.
Question 2 Multiple Choice
Why do antipsychotic medications reduce hallucinations and delusions but have limited effect on negative symptoms like avolition and flat affect?
AAntipsychotics target serotonin receptors, which control sensory experiences but not motivation
BPositive symptoms are more severe, so medications are designed to prioritize them
CAntipsychotics block D2 dopamine receptors, reducing mesolimbic hyperactivity that drives positive symptoms, while the mesocortical hypoactivity underlying negative symptoms may be worsened
DNegative symptoms appear before positive ones and have become permanent by the time treatment starts
The dopamine hypothesis proposes a circuit dissociation: mesolimbic pathway hyperactivity drives aberrant salience attribution — the feeling that random events are meaningful and threatening — which underlies hallucinations and delusions (positive symptoms). Mesocortical pathway hypoactivity contributes to motivational and cognitive deficits (negative symptoms). D2 antagonists block the hyperactive mesolimbic pathway. However, they may also reduce mesocortical activity, potentially worsening negative symptoms. This neurochemical dissociation between circuits explains the therapeutic asymmetry.
Question 3 True / False
Negative symptoms of schizophrenia (such as avolition and flat affect) tend to be more functionally disabling in daily life than positive symptoms, and are also more difficult to treat with current antipsychotic medications.
TTrue
FFalse
Answer: True
True. While positive symptoms like hallucinations are dramatic and distressing, negative symptoms often determine long-term functional outcome — a person lacking motivation, emotional expression, and social engagement struggles to maintain employment and relationships even when hallucinations are controlled. Positive symptoms respond reasonably well to antipsychotic D2 blockade. Negative symptoms largely lack effective pharmacological treatment and often persist even when positive symptoms remit, driving research into next-generation treatments targeting glutamate and other systems.
Question 4 True / False
The term 'positive symptoms' in schizophrenia refers to symptoms that are mild, easily treated, or represent a positive prognosis for recovery.
TTrue
FFalse
Answer: False
False. 'Positive' here means 'added to' normal experience — hallucinations, delusions, and disorganized speech are experiences not present in ordinary consciousness that emerge in schizophrenia. The term is purely descriptive of the direction of change (addition vs. subtraction), not a value judgment about severity or prognosis. Positive symptoms can be severely distressing and associated with dangerous behavior. The naming convention ('positive' = added, 'negative' = subtracted) comes from neurological tradition and is one of the most consistently misunderstood terms in clinical psychiatry.
Question 5 Short Answer
Why does the duration of untreated psychosis (DUP) matter for long-term prognosis, and what does this imply about the timing of intervention?
Think about your answer, then reveal below.
Model answer: Longer DUP is associated with worse cognitive outcomes, greater social deterioration, and reduced treatment response. Each additional month of untreated psychosis corresponds to measurable losses in cognitive function and social recovery capacity. This implies that intervening early — ideally before the full schizophrenia threshold is met, during the prodromal phase — produces significantly better long-term trajectories. Early Intervention in Psychosis (EIP) programs aim to minimize DUP through rapid assessment and treatment initiation.
The mechanism behind DUP's effect on prognosis is debated but likely involves neurotoxic effects of untreated psychosis (excitotoxicity, oxidative stress), progressive disengagement from educational and social networks that are difficult to re-enter, and sensitization of dopaminergic pathways. The practical implication shifts schizophrenia from a condition to manage once diagnosed to one where early detection makes a lasting difference — similar to how early treatment changes outcomes in other progressive medical conditions.